Episode 678: Episode 26-21 Big Tech’s AI Grab…

Episode 682: Episode 26-25 Why Good Companies Go Bad

On this week’s Tech Nation, what sets a great company apart from the rest? Moira speaks with Eric Ries about his book, “Incorruptible: Why Good Companies Go Bad and How Great Companies Stay Great”. Then, Dr. Steve Harr tells us how Sana Biotechnology is working to engineer insulin-producing cells for Type I diabetics, without the need for immunosuppressant drugs.

Episode 681: Episode 26-24 A Biotech Breakthrough in Antivenom

On this week’s Tech Nation, Biotech Entrepreneur, Dr. Jake Glanville, Founder, Chair and CEO of Centivax, gives us the insider’s view of the first real breakthrough in snake antivenom in 125 years, all thanks to a man who's been bitten by over 200 venomous snakes. Then, Robert Blum, CEO of CytoKinetics, shares the latest in heart failure treatment and what it could mean for extending quality of life.

Episode 680: Episode 26-23 Lawyers run the US, but Engineers run China

On this week’s Tech Nation, Dan Wang from Stanford University’s Hoover History Lab sees the similarities between China and the US in his book: “Breakneck: China’s Quest to Engineer the Future”, and finally - the development of a simple wearable to gauge your true hydration levels. Brisbane, Australia's Dr. Mark Kendall from WearOptimo tells us how it works

Episode 679: Episode 26-22 A Leap Forward in Neuroscience

On this week’s Tech Nation, Moira speaks with Dr. Cory Nicholas, Co-Founder and CEO of Neurona Therapeutics, about a breakthrough in neuroscience that leads to a new therapy showing lasting success in epilepsy. There's potential for Parkinson's, Alzheimer's, PTSD, and more.

Episode 678: Episode 26-21 Big Tech’s AI Grab…

On this week’s Tech Nation, Moira speaks with Pulitzer Prize-winning journalist Gary Rivlin about his new book, “AI Valley: Microsoft, Google, and the Trillion-Dollar Race to Cash In on Artificial Intelligence”, exposing the big names and deeper stories behind the modern AI race. Then, Ossium Health CEO Kevin Caldwell shares how cryo-banked bone marrow may one day mean no one has to wait for a living match.